Spots Global Cancer Trial Database for refractory follicular lymphoma

Every month we try and update this database with for refractory follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	NCT04007029	CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	NCT00723099	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg...	Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ...	- 69 Years	Fred Hutchinson Cancer Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.	NCT03150329	Grade 3b Follic... Recurrent B-Cel... Recurrent Class... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Prima... Recurrent Trans... Refractory B-Ce... Refractory Clas... Refractory Diff... Refractory Foll... Refractory Prim... Refractory Tran...	Laboratory Biom... Pembrolizumab Vorinostat	18 Years -	City of Hope Medical Center
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation	NCT06068881	Follicular Lymp... Refractory Foll...	Tazverik (Tazem...	18 Years -	Ipsen
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma	NCT05152459	Recurrent Folli... Refractory Foll...	Tazemetostat Ublituximab Umbralisib	18 Years -	City of Hope Medical Center
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	NCT01381692	Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal...	Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus	18 Years -	National Cancer Institute (NCI)
TGR1202 in Relapsed and Refractory Follicular Lymphoma	NCT03178201	Follicular Lymp...	TGR-1202	18 Years -	Columbia University
TGR1202 in Relapsed and Refractory Follicular Lymphoma	NCT03178201	Follicular Lymp...	TGR-1202	18 Years -	Columbia University
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	NCT03019640	Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Recurrent Indol... Refractory Diff... Refractory Foll... Refractory Indo...	Autologous Hema... Carmustine Cord Blood-deri... Cytarabine Etoposide Filgrastim Lenalidomide Melphalan Rituximab	15 Years - 70 Years	M.D. Anderson Cancer Center
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy	NCT05848765	Relapsed Follic... Refractory Foll...	Epcoritamab Lenalidomide Rituximab Obinutuzumab Bendamustine Vincristine Doxorubicin Cyclophosphamid... Prednisone Investigation a... Investigation a...	18 Years -	University of Birmingham
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	NCT04205409	Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Non-H... Recurrent Plasm... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Marg... Refractory Non-... Refractory Plas... Recurrent Mantl... Refractory Mant...	Nivolumab	18 Years -	University of Washington
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	NCT02992522	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell	Lenalidomide Obinutuzumab Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	NCT02992522	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell	Lenalidomide Obinutuzumab Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma	NCT01779791	Lymphoma	PCI-32765 (Ibru...	18 Years -	Janssen Research & Development, LLC
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma	NCT02927964	Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Folli... Refractory Foll... Mantle Cell Lym... Marginal Zone L...	Ibrutinib Radiation Thera... TLR9 Agonist SD...	18 Years -	Stanford University
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma	NCT03401853	Recurrent Diffu... Recurrent Folli... Refractory Diff... Refractory Foll...	Laboratory Biom... Pembrolizumab Rituximab Obinutuzumab	18 Years -	University of Washington
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	NCT02869633	Blastoid Varian... Recurrent Chron... Recurrent Folli... Recurrent Hodgk... Recurrent Mantl... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Mant...	Ibrutinib Laboratory Biom...	18 Years -	Vanderbilt-Ingram Cancer Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies	NCT05828589	Relapsed Non-Ho... Refractory Non-... Relapsed Chroni... Refractory Chro... Relapsed Follic... Relapsed Margin... Relapse Diffuse... Relapsed Small ... Refractory Foll... Refractory Marg... Refractory Smal... Richter Transfo... Refractory Diff... Transformed Non...	BGB-21447	18 Years -	BeiGene
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma	NCT01849263	Grade 3a Follic... Recurrent Grade... Recurrent Grade... Recurrent Grade... Refractory Foll...	Ibrutinib Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT02332980	Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac...	Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies	NCT05828589	Relapsed Non-Ho... Refractory Non-... Relapsed Chroni... Refractory Chro... Relapsed Follic... Relapsed Margin... Relapse Diffuse... Relapsed Small ... Refractory Foll... Refractory Marg... Refractory Smal... Richter Transfo... Refractory Diff... Transformed Non...	BGB-21447	18 Years -	BeiGene
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation	NCT06068881	Follicular Lymp... Refractory Foll...	Tazverik (Tazem...	18 Years -	Ipsen
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma	NCT02956382	Refractory Foll... Relapsed Follic...	Ibrutinib Venetoclax	18 Years -	Georgetown University
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.	NCT03150329	Grade 3b Follic... Recurrent B-Cel... Recurrent Class... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Prima... Recurrent Trans... Refractory B-Ce... Refractory Clas... Refractory Diff... Refractory Foll... Refractory Prim... Refractory Tran...	Laboratory Biom... Pembrolizumab Vorinostat	18 Years -	City of Hope Medical Center
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	NCT02992522	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell	Lenalidomide Obinutuzumab Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma	NCT03579927	CD19 Positive Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Refractory B-Ce... Refractory Diff... Refractory Foll...	Autologous Hema... Carmustine Cytarabine Etoposide Filgrastim Melphalan Rituximab Umbilical Cord ...	18 Years - 70 Years	M.D. Anderson Cancer Center
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma	NCT02568553	Recurrent Burki... Recurrent Diffu... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Gray-... Recurrent Mantl... Recurrent Margi... Recurrent Media... Recurrent Non-H... Recurrent Small... Refractory Burk... Refractory Diff... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Gray... Refractory Mant... Refractory Marg... Refractory Medi... Refractory Non-... Refractory Smal...	Blinatumomab Lenalidomide	18 Years -	National Cancer Institute (NCI)
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation	NCT06068881	Follicular Lymp... Refractory Foll...	Tazverik (Tazem...	18 Years -	Ipsen
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation	NCT06068881	Follicular Lymp... Refractory Foll...	Tazverik (Tazem...	18 Years -	Ipsen
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	NCT03019640	Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Recurrent Indol... Refractory Diff... Refractory Foll... Refractory Indo...	Autologous Hema... Carmustine Cord Blood-deri... Cytarabine Etoposide Filgrastim Lenalidomide Melphalan Rituximab	15 Years - 70 Years	M.D. Anderson Cancer Center
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	NCT01955499	Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Ibrutinib Lenalidomide Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma	NCT01995669	Grade 3a Follic... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Refractory Foll... Refractory Marg... Refractory Smal...	Laboratory Biom... Lenalidomide Obinutuzumab	18 Years -	M.D. Anderson Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma	NCT03583424	Hematopoietic C... Recurrent Diffu... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Non-H... Refractory Diff... Refractory Foll... Refractory Marg... Refractory Non-... Refractory Tran...	Carmustine Cytarabine Etoposide Hematopoietic C... Melphalan Venetoclax	19 Years -	Ohio State University Comprehensive Cancer Center
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas	NCT03598998	Anaplastic Larg... Nodal Periphera... Recurrent Anapl... Recurrent Angio... Recurrent Enter... Recurrent Folli... Recurrent Hepat... Recurrent Matur... Recurrent Monom... Recurrent Mycos... Recurrent Perip... Refractory Anap... Refractory Angi... Refractory Ente... Refractory Foll... Refractory Hepa... Refractory Matu... Refractory Myco... Refractory Peri... Subcutaneous Pa...	Pembrolizumab Pralatrexate	18 Years -	City of Hope Medical Center
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	NCT01897012	MYC Positive Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Hodgk... Recurrent Mantl... Recurrent Matur... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory High... Refractory Hodg... Refractory Mant... Refractory Matu...	Alisertib Laboratory Biom... Romidepsin	18 Years -	National Cancer Institute (NCI)
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma	NCT04699461	Relapsed Follic... Refractory Foll...	Loncastuximab T... Idelalisib	18 Years -	ADC Therapeutics S.A.
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	NCT04007029	CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	NCT01381692	Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal...	Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus	18 Years -	National Cancer Institute (NCI)
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies	NCT06343376	Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Mantl... Recurrent Trans... Recurrent Trans... Refractory Chro... Refractory Diff... Refractory Foll... Refractory High... Refractory Mant... Refractory Tran... Refractory Tran...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Echocardiograph... EGFRt/19-28z/IL... Fludarabine Pho... Leukapheresis Multigated Acqu... Positron Emissi...	18 Years -	Roswell Park Cancer Institute
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma	NCT04699461	Relapsed Follic... Refractory Foll...	Loncastuximab T... Idelalisib	18 Years -	ADC Therapeutics S.A.
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma	NCT03147885	Diffuse Large B... Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Indol... Recurrent Mantl... Recurrent Margi... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Mant... Stage III Non-H... Stage IV Non-Ho... Transformed Rec...	Selinexor	18 Years -	Barbara Ann Karmanos Cancer Institute
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT02332980	Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac...	Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma	NCT05025800	Aggressive B-Ce... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Composite Lymph... Indolent B-Cell... Refractory Aggr... Refractory Foll... Refractory Grad... Refractory High... Refractory Mant... Refractory Marg... Refractory Prim... Refractory Tran... Refractory Tran... Richter Syndrom...	CD47 Antagonist... Lenalidomide Rituximab	18 Years -	M.D. Anderson Cancer Center
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	NCT02950220	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Mediastinal Lym... Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Walde... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant...	Ibrutinib Laboratory Biom... Pembrolizumab	18 Years -	Ohio State University Comprehensive Cancer Center
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma	NCT04762160	Follicular Lymp...	Tazemetostat Rituximab	18 Years -	Ipsen
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	NCT04578600	Indolent B-Cell... Recurrent B-Cel... Recurrent Chron... Recurrent Mucos... Recurrent Folli... Recurrent Hairy... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Chro... Refractory Muco... Refractory Foll... Refractory Hair... Refractory Lymp... Refractory Mant... Refractory Marg... Recurrent Small... Refractory Smal...	Lenalidomide Obinutuzumab Oral Azacitidin...	18 Years -	University of California, Davis
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma	NCT02927964	Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Folli... Refractory Foll... Mantle Cell Lym... Marginal Zone L...	Ibrutinib Radiation Thera... TLR9 Agonist SD...	18 Years -	Stanford University
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	NCT04007029	CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab	18 Years - 70 Years	Jonsson Comprehensive Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: